I will once more mention a potential change of paradigms here with educating the public. Each patient who took the drug is unique. Do we have any information on other drugs they were taking at the same time? Groups will continue to advise against the use until the full facts are known...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-31-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, drugs, healthcare, Pharma, PHR, FDA, Marketing, paradigms, personal heatlh records
I wonder if all the name brand companies will one day have nothing but generics? (grin). There’s always this interesting topic too, biosimilars. “Because biosimilars aren't exact duplicates of the original drugs, they don't violate the original drug's patent , enabling legal distribution...
Whistle blowers today seem to be playing a role in the move towards transparency in more ways than one, not to mention the bounty that could be there if a case goes to court and wrongdoing is found to be the case. BD A New Jersey arbitrator ruled that a former Amgen sales rep can proceed with a...
Whistle blower case where Pharma Sales representative created an investigation and settlement. Whistle blowers can and do receive portions of settlements, and in this case there was $46 million. The uses marketed by Cephalon were not approved by the FDA. Doctors can prescribe...
I was reading another blog, and realized Comedy Central now has their own site with videos and ran across this classic from the Today Show. With all the recent discussions on how big Pharma spends money and recent marketing techniques, here it is in all it's glory. BD http://www.thedailyshow...
The meaning of advantage is below. Who knows what might be uncovered next as this may or may not be just a Merck issue, but as documents and other items of years past surface, this is what we have, sell, sell, sell, and it's perhaps not unlikely that some of these items and issues could exist...